Immutep : AGM 2021 - CEO's presentation

2021 AGM Presentation

Marc Voigt, CEO

The global leader in developing LAG-3 therapeutics

Notice: Forward-Looking Statements

The purpose of the presentation is to provide an update of the business of Immutep Limited ACN 009 237 889 (ASX:IMM; NASDAQ:IMMP). These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarification. Accordingly, these slides and the information they contain should be read in conjunction with past and future announcements made by Immutep and should not be relied upon as an independent source of information. Please refer to the Company's website and/or the Company's filings to the ASX and SEC for further information.

The views expressed in this presentation contain information derived from publicly available sources that have not been

independently verified. No representation or warranty is made as to the accuracy, completeness or reliability of the information.

Any forward-looking statements in this presentation have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside Immutep's control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this presentation include known and unknown risks. Because actual results could differ materially to assumptions made and Immutep's current intentions, plans, expectations and beliefs about the future, you are urged to view all forward-looking statements contained in this presentation with caution.

This presentation should not be relied on as a recommendation or forecast by Immutep. Nothing in this presentation should be

construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction. This presentation was authorised for release by the CEO, Marc Voigt.

General Overview

FY21 saw Immutep transform into a late-stage biotech with more trials,

partners and industry momentum than ever

	Global leadership	Exciting potential of	Strengthened
	position in LAG-3	lead product	partnerships &
	with 4 LAG-3 related	candidate efti as a	collaborations with
	product candidates	combination therapy	large pharma
	in immuno-oncology	following compelling	industry leaders
	and autoimmune	clinical data & strong
	disease	rationale to combine
		with multiple FDA
		approved treatments

LAG-3 Pioneer: French immunologist

Prof Frédéric Triebel, Immutep CMO & CSO

LAG-3 is a validated immune checkpoint

Existing approved immuno-oncology therapies target:

PD-1 &

PD-L1CTLA-4

e.g.e.g.

LAG-3 was validated by BMS in a Phase III trial (ASCO 2021)

Immutep is positioned to lead in LAG-3 with more LAG-3 related programs than any other pharma or biotech